CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 1, 2013
Result type: Reports
Project Number: SR0356-000
Product Line: Reimbursement Review

Generic Name: Sofosbuvir

Brand Name: Sovaldi

Manufacturer: Gilead Sciences Canada Inc.

Therapeutic Area: Hepatitis C, chronic

Indications: Hepatitis C, chronic

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: August 18, 2014

Recommendation Type: List with criteria/condition